Epithelioid Sarcoma

The FDA granted priority review to the following therapies in development for oncology and hematology indications:

The FDA granted accelerated approval to tazemetostat for patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.

The FDA’s Oncologic Drugs Advisory Committee, or ODAC, today voted 11-0 in favor of approval of tazemetostat for the treatment of adults with metastatic or locally advanced epithelioid sarcoma who are not eligible for curative surgery.